Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in Patients with BCG-naive High-Risk NMIBC By Ogkologos - July 22, 2025 428 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CREST study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 Fructose Fuels Cancer Growth Indirectly, Lab Study Finds January 14, 2025 Woman Perfectly Breaks Down Grief Using ‘Ball In The Box’ Analogy... March 8, 2019 Food for Thought: A Fresh Perspective on Nutrition February 5, 2021 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical... A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... Nirogacestat May Offer Hope to People with Desmoid Tumors
